secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aktis Oncology, Inc. (AKTS)
CIK:        0002035832
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001193125-26-132524
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aktis Oncology: FDA clears IND for AKY-2519; full-year 2025 net loss widens to $63.7M
--------------------------------------------------------------------------------

- FDA cleared IND for AKY-2519 (B7-H3 miniprotein radioconjugate); Phase 1b trial for solid tumors expected mid-2026.
- AKY-1189 (Nectin-4) granted Fast Track designation for urothelial cancer in Feb 2026; Phase 1b enrolling.
- Pro forma cash of $562.1M (incl. $335.3M net from Jan 2026 IPO) expected to fund operations into 2029.
- FY2025 net loss $63.7M vs $44.0M; R&D spend $67.5M (+65% YoY) driven by clinical advancement.
- Collaboration revenue from Eli Lilly partnership totaled $6.5M in FY2025, up from $1.5M in FY2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2035832/000119312526132524/0001193125-26-132524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2035832/000119312526132524/ck0002035832-20260330.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-132524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer